PIP and breast carcinoma: In a distinct investigation encompassing a cohort of 111 patients, the presence of antibodies targeting GCDFP-15/gp17 was assessed, revealing their detection in both individuals afflicted with mammary carcinoma and those with benign breast conditions [87].